Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH301:11

ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3

7.4K
All ortho–para directors, excluding halogens, are activating groups. These groups donate electrons to the ring, making the ring carbons electron-rich. Consequently, the reactivity of the aromatic ring towards electrophilic substitution increases. For instance, the nitration of anisole is about 10,000 times faster than the nitration of benzene. The electron-donating effect of the methoxy group in anisole activates the ortho and para positions on the ring and stabilizes the corresponding...
7.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

643
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
643
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.5K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.5K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

594
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
594

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diamine ligands enhance photodynamic inactivation of gram-negative bacteria using 5-aminolevulinic acid.

Bioorganic chemistry·2026
Same author

Optimization of fluorogenic CatS substrates for monitoring cancer-associated proteolytic activity.

Analytical biochemistry·2026
Same author

Utility of FRET substrates in bladder cancer diagnosis.

Bioorganic chemistry·2026
Same author

Podocytes as novel sources of neutrophil serine proteases: expression and regulation by inflammatory molecular patterns.

Cellular and molecular life sciences : CMLS·2025
Same author

A Novel Role of Neutrophil Elastase in Podocyte Dysfunction Induced by High Glucose, PMA, and MDP.

Journal of cellular physiology·2025
Same author

Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target.

The European respiratory journal·2025

Related Experiment Video

Updated: Jan 27, 2026

Optimized Procedure for Determining the Adsorption of Phosphonates onto Granular Ferric Hydroxide using a Miniaturized Phosphorus Determination Method
08:21

Optimized Procedure for Determining the Adsorption of Phosphonates onto Granular Ferric Hydroxide using a Miniaturized Phosphorus Determination Method

Published on: May 18, 2018

15.1K

Proteinase 3 phosphonic inhibitors.

Renata Grzywa1, Adam Lesner2, Brice Korkmaz3

  • 1Wroclaw University of Science and Technology, Faculty of Chemistry, Division of Medicinal Chemistry and Microbiology, Wybrzeże Wyspiańskiego 27, 50-370, Wrocław, Poland.

Biochimie
|March 17, 2019
PubMed
Summary

Proteinase 3 (PR3) is key in immunity but causes inflammation when active. This study details new phosphonic inhibitors designed to control PR3 activity, offering a novel therapeutic approach.

Keywords:
Activity-based probesAminophosphonatesInhibitorsNeutrophil serine proteasesProteinase 3

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.5K

Related Experiment Videos

Last Updated: Jan 27, 2026

Optimized Procedure for Determining the Adsorption of Phosphonates onto Granular Ferric Hydroxide using a Miniaturized Phosphorus Determination Method
08:21

Optimized Procedure for Determining the Adsorption of Phosphonates onto Granular Ferric Hydroxide using a Miniaturized Phosphorus Determination Method

Published on: May 18, 2018

15.1K
Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.5K

Area of Science:

  • Immunology
  • Biochemistry
  • Medicinal Chemistry

Background:

  • Neutrophils are vital immune cells defending against pathogens.
  • Proteinase 3 (PR3), a neutrophil serine protease, plays roles in immunity and inflammation.
  • Uncontrolled PR3 activity contributes to inflammatory diseases and tissue damage.

Purpose of the Study:

  • To review the historical context of Proteinase 3 (PR3) research.
  • To present recent advancements in the design and synthesis of PR3 inhibitors.
  • To evaluate the activity of novel phosphonic PR3 inhibitors.

Main Methods:

  • Literature review of PR3 characterization and inhibitor development.
  • Chemical synthesis of novel phosphonic compounds.
  • In vitro assays to assess PR3 inhibitory activity.

Main Results:

  • PR3's dual role in host defense and inflammatory pathology is highlighted.
  • Novel phosphonic inhibitors targeting PR3 have been successfully designed and synthesized.
  • Initial activity data for these phosphonic inhibitors against PR3 are presented.

Conclusions:

  • Targeting PR3 activity offers a potential strategy for managing inflammatory conditions.
  • Phosphonic inhibitors represent a promising class of therapeutic agents for PR3-mediated diseases.
  • Further research is warranted to optimize these inhibitors for clinical application.